

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

8

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁴ : C12P 21/02, C07K 1/00		A1	(11) International Publication Number: WO 90/01555 (43) International Publication Date: 22 February 1990 (22.02.90)
(21) International Application Number: PCT/DK89/00193 (22) International Filing Date: 14 August 1989 (14.08.89) (30) Priority data: 4521/88 12 August 1988 (12.08.88) DK		(74) Agent: HOFMAN-BANG & BOUTARD A/S; Adelgade 15, DK-1304 Copenhagen K (DK). (81) Designated States: AU, DK, FI, HU, JP, US. Published <i>With international search report.</i>	
(71) Applicant (<i>for all designated States except US</i>): CARLSBERG BIOTECHNOLOGY LTD. A/S [DK/DK]; Tagensvej 16, DK-2200 Copenhagen N (DK). (72) Inventors; and (75) Inventors/Applicants (<i>for US only</i>) : AASMUL-OLSEN, Stig [DK/DK]; Skodsborgvej 410, sttv., DK-2942 Skodsborg (DK). THORBEK, Pia [DK/DK]; Sdr. Jagtvej 39, DK-2970 Hørsholm (DK). WIDMER, Fred [CH/DK]; Carlsberg Biotechnology Ltd. A/S, Tagensvej 16, DK-2200 Copenhagen N (DK). HANSEN, Søren [DK/DK]; Tomsgaardsvej 102, DK-2400 Copenhagen NV (DK).			
(54) Title: A PROCESS FOR ENZYMATIC PRODUCTION OF DIPEPTIDES OR STRUCTURALLY RELATED COMPOUNDS			
(57) Abstract <p>Dipeptides H-A-B-Y, wherein A is an α- or ω-amino acid residue, B is an α-aminocarboxylic, aminophosphonic acid or aminosulfonic acid residue, and Y is OH, H or a C-terminal protective group, are produced by reacting a substrate component: H-A-OR¹ or H-A-NR²R³, wherein R¹, R², R³ are alkyl, aryl or aralkyl or R² and R³ are H, with a nucleophile component selected from aminocarboxylic acids or their amides, esters, aldehydes or ketones: H-B-NR²R³, H-B-OR⁴ or H-B-R⁵, wherein B, R² and R³ are as defined above, R⁴ and R⁵ are alkyl, aryl or aralkyl or R⁵ is H, or aminophosphonic or aminosulfonic acids, in the presence of an amidase or esterase enzyme different from serine or thiol carboxypeptidases, preferably a serine or thiolendopeptidase, lipase, esterase or glycosidase in solution or dispersion, and then, if desired, cleaving a present side-chain protecting group or protective group Y. The process allows for production of LL-, LD-, DL- and DD-dipeptides without risk of racemization in a simple and economic manner.</p>			


FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT Austria	ES Spain	MG Madagascar
AU Australia	FI Finland	ML Mali
BB Barbados	FR France	MR Mauritania
BE Belgium	GA Gabon	MW Malawi
BF Burkina Faso	GB United Kingdom	NL Netherlands
BG Bulgaria	HU Hungary	NO Norway
BJ Benin	IT Italy	RO Romania
BR Brazil	JP Japan	SD Sudan
CA Canada	KP Democratic People's Republic of Korea	SE Sweden
CF Central African Republic	KR Republic of Korea	SN Senegal
CG Congo	LI Liechtenstein	SU Soviet Union
CH Switzerland	LK Sri Lanka	TD Chad
CM Cameroon	LUX Luxembourg	TG Togo
DE Germany, Federal Republic of	MC Monaco	US United States of America
DK Denmark		

A process for enzymatic production of dipeptides or structurally related compounds

The present invention concerns a process for enzymatic
5 production of dipeptides and derivatives of dipeptides and having the general formula



10 wherein A represents an optionally side-chain protected L- or D- α -amino acid residue or ω -amino acid residue and B represents an optionally side-chain protected L- or D- α -aminocarboxylic acid residue which may be the same as or different from A, and L- or D-aminophosphonic acid residue
15 or L- or D-aminosulfonic acid residue or the corresponding ω -amino acids or salts and hydrates thereof, and Y is OH, H, alkyl, aryl, aralkyl or a C-terminal blocking group, or BY represents an amino alcohol residue



wherein B^1 is a decarboxy derivative of the aminocarboxylic acids as defined with relation to B, and Y^1 is H, alkyl, aryl or aralkyl.

25 In recent years there has been an increasing interest in dipeptides and dipeptide derivatives optionally containing an amino acid residue of D-configuration, with a view to their potential pharmacological effects, such as e.g.
30 antibiotics. Likewise, there has been a great interest in dipeptides within fields such as artificial nutrition - human as well as veterinary -sweeteners and within agrochemistry, such as e.g. herbicides.

35 Such dipeptides H-A-B-Y can be produced by means of known chemical coupling reactions, but all these methods share

the feature that, generally, it is necessary to protect the amino acids involved - A and B - on the amino-group and the carboxylic acid group, respectively, and frequently also on the side chains if these carry 5 functional groups. Further, there is an inherent risk of side reactions during the chemical coupling step because of the reagents and conditions employed, a major side reaction being racemization, particularly of the A-component. By replacing the chemical coupling step with an 10 enzymatic coupling step proceeding under mild conditions, such side reactions and racemization can be avoided, yielding a stereochemically pure product.

The presence of amino- and carboxyl protective groups is 15 mandatory in chemical coupling and has generally been regarded as mandatory also in prior art enzymatic coupling using endoproteases.

This adds several undesired features to these processes 20 seriously afflicting their process economy on an industrial scale, particularly apparent in dipeptide synthesis.

The disadvantages are concerned with the introduction of 25 these groups, as well as their removal and presence during process operation, increasing overall process cost and time and affecting overall yield.

Typical examples of amino protective groups commonly used 30 are those of the carbobenzoxy (Z-) and tert-butoxycarbonyl (Boc-) type, which are of a molecular weight comparable to those of the amino acid residues. Firstly, the protective groups will have to be introduced in the starting materials by means of appropriate costly agents in a 35 separate reaction step followed by an isolation step. While present, these hydrophobic groups often have a

drastical effect upon the solubility of the intermediates and reaction products, and may afflict both the nature and the amount of solvents required in their processing as well as ease of purification and of deprotection. The 5 deprotection will also take place in a separate step with a following purification step.

For this purpose a series of reactions are available, but with the exception of catalytical hydrogenation, posing 10 industrial problems of its own, these methods are occurring under violent, often strongly acidic or basic conditions, frequently giving rise to a series of side reactions, resulting in an impure product or demanding laborious purification.

15 The last steps in this relatively long series of synthesis steps may thus be a rather comprehensive deprotection to obtain the desired peptides, and, owing to the almost inevitable secondary reactions, rather laborious 20 purification procedures are frequently required to provide a product with the desired high purity.

A dipeptide which has attracted great attention in recent years is L-Asp-L-Phe-methylester, also known as aspartame, 25 and derivatives thereof which has found extended use as sweeteners. The chemical synthesis of aspartame is entailed with the above-mentioned drawbacks.

Attempts to avoid amino terminal protection in the 30 production of aspartame and its derivatives have led to microbial fermentation approaches, like the fermentation processes described in EP-A1-074095, EP-A2-102529 and EP-A2-154472. This technique is fundamentally different from synthetic approaches and relies on specific organisms for 35 aspartame, and is thus not generally applicable in connection with other dipeptides. In addition, the yields

are low and recovery from the fermentation broth laborious.

The above-mentioned shortcomings in the known processes for the production of aspartame are confirmed in EP-A2-269390. In this application a method for producing L-Asp-L-Phe-alkylesters is claimed which comprises reacting in a solvent medium L-aspartic acid alpha ester or L-aspartic acid alpha amide with L-phenylalanine alkyl ester in the presence of an enzyme, microorganism containing the enzyme, enzyme containing fraction of a microorganism, or enzyme immobilized on solid support, said enzyme being capable of forming L-aspartyl-L-phenylalanine alkyl ester by condensation of the L-aspartic acid alpha ester or L-aspartic acid alpha amides and L-phenylalanine alkyl ester.

It is seen that an enzyme must be used which has specific esterase or amidase activity against Asp, but not against Phe. The only enzyme mentioned is the extracellular protease with esterolytic activity of *Staphylococcus aureus* V8.

While therefore the applicability of N- α -unprotected Asp-esters or amides is suggested - along with N-protected or β -esters or amides - the disclosure of one specific enzyme for the use in the production of a specific peptide supported only by one example where rather peculiar reaction conditions are used, viz. 5 times excess of substrate components, this reference does not by far provide a general teaching of the applicability of N-unprotected substrate components in dipeptide synthesis catalyzed by amidase or esterase enzymes.

Thus, it is an obvious advantage in terms of overall process economy to be able to avoid protective groups,

also on the amino and carboxy terminus. In some cases, it may be of interest to be able to produce a dipeptide having side-chain protection, but no terminal protection, and it will be shown that it is possible in the process 5 according to this invention, starting from side-chain protected, but amino unprotected starting materials. In this case, the same advantages of mild reaction conditions and overall process economy may be obtained. If desired, the side-chain protective group may be removed by chemical 10 or enzymatic means, generally under milder conditions than amino protective groups.

The enzyme catalyzed coupling reactions enabling the use of optionally side-chain unprotected amino acid 15 derivatives and an optionally C-terminal unprotected B-component (nucleophile) are known. See e.g. the DK Patent Specification No. 155613 as well as the corresponding EP Patent Specification No. 17 485 (EP-B1-17485), incorporated herein by reference.

20 Briefly, EP-B1-17485 describes a process for producing peptides by reacting a substrate component selected from i.a. amino acid esters and amino acid amides with an amine component (nucleophile) selected from i.a. L-amino acid 25 amides, L-amino acids or L-amino acid esters in the presence of an L-specific serine or thiol carboxypeptidase enzyme.

If a dipeptide is to be produced by the process of EP-B1- 30 17485, the substrate component is obligatory an N-terminal protected amino acid derivative, and the constituent amino acid is obligatory an L-amino acid.

As described in EP-A1-278787, (incorporated by reference) 35 and other applications claiming priority from DK appln. 725/87 filed on February 13, 1987 it was surprisingly

found that the serine and thiol carboxypeptidases used in EP-B1-17485 are capable of utilizing N-unprotected amino acid esters or amides as a substrate component in controlled reactions for synthesis of dipeptides and 5 dipeptide derivatives, and that it was possible to suppress a possible oligomerization of the substrate.

Admittedly, it has long been known that some endoproteases can catalyze oligomerization of certain N-unprotected 10 amino acid esters with L-configuration, (Fruton, J.S. Advances in Enzymology, 53: 239-306, 1982) but it has never been attempted to use this for production of dipeptides which are not simple dimers. Generally, the results of such oligomerizations have been a mixture of a 15 series of oligomers, sometimes long. The degree of oligomerisation and complexity of the mixture depend on the solubility of the products formed. Also it should be mentioned that the mere fact that a given enzyme can hydrolyze a particular N- α unprotected amino acid 20 derivative does not automatically lead to a similar ability to catalyze coupling reactions involving the same derivative. See the references cited by Andersen, A.J. in "Peptides, Structure and Function". Proc. of the Ninth ann. peptide symposium, Eds. Deber, C.M. et al., Pierce 25 (1985), p. 355.

For this reason the use of serine and thiol endoproteases for peptide synthesis has been limited to the use of amino and carboxy terminal protected starting materials, as 30 exemplified by US-A-4.086.136, where e.g. papain, stem bromolein, ficin, chymopapain and chymotrypsin are mentioned.

Furthermore, for these enzymes free amino acids have so 35 far generally been regarded as unsuitable as amino components as noted by Y.W. Mitin et al., Int. J. Peptide

Protein Res., Vol. 23 (1984), p. 528-534.

The above-mentioned amino and carboxy terminal protected starting materials are also mandatory if aspartate

5 endoproteases e.g. pepsin are used as exemplified by US-A-3.972.773, and if metallo endoproteases are used, as exemplified by the synthesis of Z-AspPheOMe.PheOMe-salt in EP-A1-009585. In these condensation type reactions it is further mandatory that the substrate component is on the
10 free α -carboxylic acid form, as exemplified in EP-A2-220923.

The use of amino and carboxy terminal protected starting materials has also been considered mandatory for

15 nonproteases, e.g. esterases with amidase activity, Blair West et al., Tetrahedron letters, Vol. 28. No. 15, p. 1629-32, (1987), who used porcine pancreatic lipase, Candida cylindracea lipase and pig liver esterase in organic media, optionally containing an aqueous buffer.

20

Cellulases in turn, have so far only been used synthetically for polymerisation condensation type reactions of completely free β -amino acids as described by Kitazume, T. et al., J. Flourine Chem. 36 (1987), p. 225-

25 236.

The synthesis of the diastereomeric dipeptides of DL, LD and DD-configuration as well as peptides containing β -amino acid residues from amino-unprotected substrate

30 components has so far not been possible with carboxypeptidases except as described with relation to EP-A1-278787 nor in general with any proteolytical enzymes (Class EC 3.4). Some efforts have been made with a different class of enzymes, aminoacyl-t-RNA-synthetase
35 (Class EC 6.1) as exemplified by EP-A1-086053. In this case a specific enzyme must be used for each type of amino

acid residue, and furthermore, expensive Co-factors like ATP are required. At the same time, yields are very poor, so even though some product was isolated and identified, typically a ten fold excess of Co-factor and a hundred 5 fold excess of nucleophile and up to a thousand fold excess of enzyme by weight was required.

A recent study by Gaertner et al., Proteins: Structure, Function and Genetics 3: 130-137 (1988) indirectly 10 confirms the prejudice against using N- α -unprotected amino acids as substrate components in enzymatic peptide synthesis. Since a major problem earlier encountered is secondary hydrolysis of the newly synthesized product, an attempt was made to decrease water activity in the 15 reaction medium by using organic solvents. Gaertner et al. reports dipeptide synthesis using chymotrypsin which had been chemically modified to enhance its solubility in organic media. Using a number of N- α -protected amino acid esters as substrates and amino acid amides as nucleophiles 20 N- α -protected dipeptide amides were obtained in good yields in a benzene medium. Thus, α -Bz-Lys-Phe-NH₂ was obtained in a yield of more than 98% by reacting α -Bz-Lys-OMe with Phe-NH₂. However, when using ϵ -Z-LysOEt, i.e. a side-chain protected but N- α -unprotected lysine ester, no 25 ϵ -Z-Lys-Phe-NH₂ was formed. Gaertner et al do not comment on this result, but it indicates that they apparently believed that amino group protection of the substrate component was compulsory.

30 The present invention which represents a further development of the invention according to EP-A1-278787 resides on the surprising finding that the capability of utilizing N- α -unprotected amino acid esters and amides of the substrate component in controlled reactions for 35 synthesis of dipeptides and dipeptide derivatives is not limited to serine or thiol carboxypeptidases, but also


possible with amidase or esterase enzymes generally, in particular serine endoproteases, thiol endoproteases, lipases and esterases.

5 Again, it was surprisingly found that also N- α -unprotected amino acid derivatives of D-configuration can be used as substrates in these reactions, so that, in addition to LL-dipeptides, it is also possible to synthesize DL-dipeptides. The reaction rate for D-substrates, however,
10 is generally somewhat lower than for L-substrates under uniform conditions, but the difference in rate is much smaller than for the corresponding N-protected amino acid esters, the D-substrate being reacted at a rate which is much smaller than the rate for the L-substrate; Purdie et
15 al., Biochem. Biophys. Acta, 268 (1972), 523. There are, however great individual differences between the enzymes in this respect. Synthesis yields are often just as high with the unprotected D-substrates in relation to the unprotected L-substrates.

20

It is known that certain endoproteases are capable of utilizing a nucleophile component having D-configuration in reactions with N-protected substrate components. Thus, depending on the actual sequence it is possible to
25 synthesize dipeptides having LL-, DL-, LD- or DD- configuration by the process according to the invention.

The process of the invention is thus characterized by reacting a substrate component, which is an amino acid derivative having the formula



35 wherein A is as defined above, R¹ represents alkyl, aryl or aralkyl optionally substituted with inert substituents

10


or an α -des-amino fragment of an amino acid, and R² and R³ are the same or different and each represents hydrogen, alkyl, aryl or aralkyl optionally substituted with inert substituents,

5

with a nucleophile component selected from


(a) amino acids having the formula

10



wherein B is an aminocarboxylic acid residue as defined above,

15 (b) amino acid amides having the formula




20

wherein B is an aminocarboxylic acid residue as defined above, and R² and R³ have the above meaning, except that when R² represents hydrogen, R³ may also represent hydroxy or amino,

25

(c) amino acid esters having the formula



30 wherein B is an aminocarboxylic acid residue as defined above, and R' represents alkyl, aryl or aralkyl,

(d) optionally acid group protected straight chain or branched aminophosphonic acids or aminosulfonic acids

35 having the formula

11



wherein R⁵, R⁶ and R⁷ independently represent hydrogen, alkyl, aryl or aralkyl, x is 1-6 and z is 2-12,

5

(e) amino acid aldehydes or ketones or derivatives thereof having the formula



10

wherein B¹ is as defined above, Y² is O or a functional derivative thereof, preferably a ketal, and R⁸ is H, alkyl, aryl or aralkyl, and

15 (f) amino alcohols having the formula



wherein B¹ and Y¹ have the above meaning

20

in the presence of an amidase or esterase enzyme different from serine or thiol carboxypeptidases in solution or dispersion, and then, if desired, cleaving a present side-chain protecting group or protective group Y and/or, if

25

desired, converting the resulting dipeptide derivative to a salt or hydrate.

Examples of useful amino acids include aliphatic amino acids, such as monoaminomonocarboxylic acids, e.g. glycine

30

(Gly), alanine (Ala), valine (Val), norvaline (Nval), leucine (Leu), isoleucine (iso-Leu) and norleucine (Nleu), hydroxy amino acids, such as serine (Ser), threonine (Thr) and homoserine (homo-Ser), sulfur-containing amino acids, such as methionine (Met) or cystine (CysS) and cysteine

35

(CysH), monoaminodicarboxylic acids, such as aspartic acid (Asp), glutamic acid (Glu) and amides thereof, such as

asparagine (Asn) and glutamine (Gln), diaminomonocarboxylic acids, such as ornithine (Orn) and lysine (Lys), arginine (Arg), aromatic amino acids, such as phenylalanine (Phe) and tyrosine (Tyr), as well as 5 heterocyclic amino acids, such as histidine (His), proline (Pro) and tryptophan (Trp). As examples of useful amino compounds of a more unusual structure may be mentioned penicillamine (Pen), aminophosphonic acids, such as alanine-phosphonic acid (AlaP), aminosulfonic acids, such 10 as taurine (Tau), ω -amino acids, such as β -alanine (BAla), iso amino acids, such as α -methylalanin (Aib), amino acids substituted with inert substituents, e.g. halogen or nitro, or the aldehyde, ketones, ketals or alcohols derived from e.g. alanine. As mentioned, they may be 15 included in D-form in the substrate component and they may also be present in D-form in the nucleophile component.


It will be understood that the definitions given for the group Y in the peptide derivative of the formula H-A-B-Y 20 are reflected in the various nucleophile components, stated in claim 1. Thus, (b) and (c) both contain C-terminal blocking groups, while Y = H corresponds to an amino acid aldehyde and Y = alkyl, aryl or aralkyl corresponds to an amino ketone. If desired a functional 25 derivative of an amino ketone may be used as nucleophile, e.g. a ketal, oxime or sulfite.

As in the process according to EP-A1-278787, the advantages of the process of the present invention over 30 the mentioned known methods are minimum or no side chain protection, no N-protection of the substrate component which may have both D- and L-configuration, no risk of racemization, few synthesis steps and an expected relatively pure end product, which in combination provides 35 an extremely simple and economic method of production.

Preferred substrate components are esters in which R¹ is a straight or branched alkyl having 1 to 8 carbon atoms, such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, amyl, hexyl, heptyl and octyl, or the aralkyl group benzyl. Particularly expedient nucleophile components are amino acid amides, in which R² is H, and R³ is H or C₁-C₆ alkyl, or amino acid esters in which R⁴ is a straight or branched alkyl having 1 to 6 carbon atoms such as the above-mentioned ones. As mentioned, R¹ may be alkyl, aryl or aralkyl optionally substituted with inert substituents, e.g. hydroxy or nitro.

The invention also comprises the processes involving intermediate formation of a peptide containing the group

15



following which this group may be cleaved to form a carboxylic acid group. This cleavage may be catalyzed by another enzyme or the same enzyme as was used to form the peptide, albeit under different reaction conditions. Also C-terminal modifications of the group Y may be made.

25

Enzymes may also be used to cleave side-chain protective groups, applicable enzymes being proteolytic enzymes, lipases and esterases, according to the nature of the protective group, see "The peptides, Analysis, Synthesis, Biology" Vol 9, Special Methods in peptide Synthesis Part C. J.A. Glass, Enzymatic manipulation of Protecting Groups in Peptide Synthesis, Academic Press 1987.

As examples of enzymes possessing esterase and/or amidase activity, and therefore expected to be active as catalysts in the process according to this invention may be

14

mentioned those listed in the table below.

For a closer description of these enzymes, reference is made to i.a. Perlmann, G. E. et al., in Colowick, S. P. & 5 Kaplan, N. O. (eds.) Methods of Enzyme. 8 (1966) 19 (1970), 28 (1972), 35 (1975) and 45 (1976), Fruton, S., Adv. Enzymol. 53, p. 239, Wiley (1982), Abassi, A. et al. Biol. Chem. Hoppe-Seyler, 367, p. 441-45 (1986), Dixon, M. and Webb E. C. "Enzymes", 3rd ed. Longman Group (1979), 10 Torrey, S. (ed.) in "Enzyme Technology, Recent Advances", Biotech. Rev. 2, Noyes Data Corporation (1983), and finally Laane, C., Tramper, S., Lilly, M. D. (eds.) "Biocatalysis in Organic Media", Elsevier (1987), Asano, Y. et al., Angew. Chem. 101, (1989), p. 511-512, Kitazume, 15 T. et al., J. Fluorine Chem. 36 (1987), p. 225-236. all being incorporated by reference.

20

25

30

35

TABEL II. Proteases different from carboxypeptidases:

5	Enzyme	(Abb)	Normal Source
A) Thiolendo-			
proteases:			
10	Papain	(P)	Papaya
	Chymopapain	(CP)	Papaya
	Bromelain	(B)	Pineapple
	Ficin	(F)	Fig (Ficus)
	Clostripain	(CL)	Clostridium histolyticum
15			
B) Serineendo-			
proteases:			
20	Trypsin	(T)	Pancreas
	Chymotrypsin	(CT)	Pancreas
	Elastase	(E)	Pancreas
	Subtilisin	(S)	Bacillus licheniformis or subtilis
	Thermitase	(TV)	Thermoactino- myces vulgaris
25	Proteinase K	(K)	Tritirachium album
	Valyl-proteinase	(VP)	Candida tropicalis
30	Post Prolin Specific Endopeptidase	(PPSE)	Flavo- bacterium meningo- septicum
35			

Achromobacter lyticus Protease I (AL-I) Achromobacter lyticus
 Endoproteinase ArgC (AC) Submaxilaris glands
 5 Endoproteinase LysC (LC) Lysobacter enzymogenes
 Thrombin (TB) Blood plasma

10 C) Exopeptidases:

Aminopeptidase (EC3.4.11)
 particularly from
 Achromobacter sp.

Animal,
 vegetable,
 or microbial

15

II. Other hydrolases acting on ester bonds

Carboxylesterase	(EC.3.1.1.1)	Liver
Arylhydrolase	(EC.3.1.1.2)	Plasma
20 Triacylglycerollipase	(EC.3.1.1.3)	Animal, particularly from Porcine Pancreas or Candida cylindracea or Lipolase® (NOVO); (Aspergillus sp.)

25

Acetic ester acetylesterase	(EC.3.1.1.6)	Animal tissue
Arylglycerol lipase	(EC.3.1.1.23)	Animal or vegetable

30

III Glycosidases

Cellulase	(EC.3.2.1.4)	Animal, vegetable, or microbial
particulary from		
35 Trichoderma viride or		
Aspergillus niger		

The presently preferred enzymes are trypsin, chymotrypsin, subtilisin, elastase, papain, chymopapain, clostripain, porcine pancreatic lipase and *Candida cylindracea* lipase.

- 5 The enzyme used may also be chemically modified or be a biosynthetic mutant of a natural form.

As illustrated more fully below, the process of the invention is rather simple.

10

The reaction may be performed in an aqueous reaction medium, if desired containing up to 90%, preferably up to 60% of a polar organic solvent which is miscible with water, and compatible with the enzyme under the conditions 15 specified. Preferred solvents are lower alcohols, dimethyl formamide, dimethyl sulfoxide, dimethoxy ethane and ethylene glycol.

It is important to maintain a rather constant pH value in 20 the reaction mixture. This pH value is between 3 and 11, preferably between 5 and 10.5, more preferably between 6 and 10 and most preferably between 7 and 9.5 and also depends upon the concrete starting materials, the peptide formed and the enzyme.

25

The reaction may alternatively be performed in a nonaqueous, nonpolar medium being composed of water immiscible organic solvents e.g. benzene, toluene, hexanes, heptanes, octanes, dialkyl ethers, ethyl acetate, 30 ethyl propionate and methylene chloride, etc. which are compatible with enzymes having esterase and/or amidase activity, in particular lipases.

These essentially apolar reaction media may contain up to 35 10% water in dissolved form in order to facilitate optimal enzyme performance or reaction stability.

The reaction temperature is preferably room temperature and above, 20 to 50°C, but temperatures in the range 0 to 80°C may be used, if advantageous under the conditions otherwise given. At high solvent conditions subzero or temperatures higher than 80°C may be used.

The concentration of the two reaction components may vary within wide limits, but the nucleophile component is frequently in excess, and to avoid oligomerization of the substrate component, said component is often added in minor portions at intervals during the entire reaction sequence. If a good nucleophile for the enzyme is used in high excess, surprisingly no oligomerization is observed, and high substrate concentrations may be used without side reactions. In case a homo-dipeptide in which A = B is wanted, oligomerization from a single nucleophile can be avoided by using different carboxy protective groups on the substrate and nucleophile component.

Thus, the starting concentration of the substrate component may typically be 0.005 to 2 molar and for the nucleophile component in cases, - where it is added separately, 0.005 to 3 molar. In most situations it is possible to recover excess of the nucleophile component and the hydrolysis product from the substrate component for optional reesterification and reuse. Recycling of the components is particularly easy because of their simple structure and the absence of side reactions and deprotective losses.

The enzyme concentration may likewise vary, but is frequently somewhat higher (5-50 µm) (or even higher, up to ~ 500 µm) than the concentrations appropriate in the use of N-protected amino acid ester substrates, but the amount required for synthetic purposes may be reduced more.

than tenfold by using a stable immobilized enzyme preparation, thereby enabling the enzyme to be used in a continuous process.

- 5 The reaction medium may also contain salts, such as NaCl and CaCl₂, which influences the binding of the enzyme to the substrate and may stabilize the enzyme, as well as a complex binding agent for present metal ions, such as EDTA, and mercaptostabilizing agents such as DTT, BME or
10 Cysteine may be used with for instance thiolendopeptidases.

This surprising hydrolysis sequence is reflected in the following examples, which illustrate the production of various dipeptides in the process of the invention using
15 various enzymes.

General method for examples 1-13 and 20 et seq.

- The reactions, performed on an analytical scale with a
20 reaction volume of 1 ml, were carried out in a pH-stat, and the selected pH value was kept constant by automatic addition of 1 N NaOH except for the examples with high content of organic solvents or immobilized enzymes, where the conditions are indicated in the individual examples.
25 Reaction temperature was room temperature, unless otherwise stated. The table also includes reaction concentrations, content of organic solvent, product and yield. Reaction times are typically between 0.5 and 5 hours and the enzyme concentrations are typically 5-20 µM.
30 unless otherwise stated.

Product identification and determination of product yield were performed by means of reverse phase HPLC (Waters 6000 A pumps, 660 gradient blender, UK 6 injector) on a C₁₈NOVA
35 PAK column (Waters, RCM) using suitable gradients of elution systems containing 50 mM triethylammonium

than tenfold by using a stable immobilized enzyme preparation, thereby enabling the enzyme to be used in a continuous process.

- 5 The reaction medium may also contain salts, such as NaCl and CaCl₂, which influences the binding of the enzyme to the substrate and may stabilize the enzyme, as well as a complex binding agent for present metal ions, such as EDTA, and mercaptostabilizing agents such as DTT, BME or
10 Cysteine may be used with for instance thiolendoproteases.

This surprising hydrolysis sequence is reflected in the following examples, which illustrate the production of various dipeptides in the process of the invention using
15 various enzymes.

General method for examples 1-13 and 20 et seq.

The reactions, performed on an analytical scale with a
20 reaction volume of 1 ml, were carried out in a pH-stat, and the selected pH value was kept constant by automatic addition of 1 N NaOH except for the examples with high content of organic solvents or immobilized enzymes, where the conditions are indicated in the individual examples.
25 Reaction temperature was room temperature, unless otherwise stated. The table also includes reaction concentrations, content of organic solvent, product and yield. Reaction times are typically between 0.5 and 5 hours and the enzyme concentrations are typically 5-20 µm.
30 unless otherwise stated.

Product identification and determination of product yield were performed by means of reverse phase HPLC (Waters 6000 A pumps, 660 gradient blender, UK 6 injector) on a C₁₈NOVA
35 PAK column (Waters, RCM) using suitable gradients of elution systems containing 50 mM triethylammonium

phosphate, pH 3.0 from 0% to 80% acetonitrile with a flow of 2 ml/min. Elution was monitored by means of a UV detector (Waters 480) at 230 nm, 254 nm, 278 nm or 290 nm.

5 The products were identified by amino acid analysis of fractions from the HPLC analysis, which corresponded to the assumed product peak and/or by HPLC comparison with a chemically synthesized reference product. These were produced according to known principles, usually via
10 reaction between BOC-A-OSu - the tertiary butyloxy carbonyl - succinic imide ester derivative of the substrate amino acid - and the used nucleophile component followed by deblocking of the N-terminal amino acid residue. In all cases, it was possible to separate LL-and
15 DD-dipeptides from the diasteromeric DL-and LD-dipeptide products.

For the products which can only be detected at 230 nm, the product yields were determined by means of the
20 absorption/concentration curve of the chemically synthesized reference compound. For the other products, the yields were determined on the basis of the ratio between the integrated areas below the peaks in the elution chromatogram, corresponding to the product
25 respectively the reactant which absorbs at the wavelength concerned.

The reaction conditions in the preparative examples 14-17 are described in the individual examples. The reactions
30 were followed on analytical HPLC as described. The enzyme concentrations are generally lower and the reaction times longer than in the corresponding analytical examples, but no attempt to optimize the reaction conditions has been made.

- 21 -
Example 1

Trypsin a) catalyzed synthesis of L,L-dipeptide amides with
5 L-Arginine ethyl ester (50 mM) as substrate and L-amino acid
amides as nucleophiles at various concentrations in water at
pH 8.5

10	<u>Nucléophile</u>	(conc.)	Product	Yield
	Leucine amide	(0.2 M)	ArgLeuNH ₂	20%
	Leucine amide	(0.7 M)	ArgLeuNH ₂	32%
	Methionine amide	(0.25 M)	ArgMetNH ₂	31%
15	Methionine amide	(0.5 M)	ArgMetNH ₂	52%
	Methionine amide	(1.0 M)	ArgMetNH ₂	90%
	Serine amide	(0.5 M)	ArgSerNH ₂	45%
	Tyrosine amide	(0.5 M)	ArgTyrNH ₂	46%

20

a) 10 μ M

25

30

35

- 22 -
Example 2

Trypsin a) catalyzed synthesis of diastereomeric L,D- and
5 D,L-dipeptide amides with L- or D-Arginine ethyl ester (50 mM) as substrate and L- or D-Leucine and Methionine amides as nucleophiles in water at pH 8.5

10	Substrate	Nucleophile	(conc.)	Product	Yield
	D-argOEt	L-Leucine amide	(0.2 M)	argLeuNH ₂	20%
	D-argOEt	L-Leucine amide	(1.0 M)	argLeuNH ₂	30%
15	D-argOEt	L-Methionine amide	(0.5 M)	argMetNH ₂	68%
	L-ArgOEt	D-methionine amide	(1.0 M)	ArgmetNH ₂	5%

a) 10 μ M

20

25

30

35

- 23 -
Example 3

Trypsin a) catalyzed synthesis of L,L-dipeptide amides using
5 L-amino acid amides (0.5 M) as nucleophiles and L-Lysine or
Histidine ethyl ester (50 mM) as substrate in water at pH
8.5

10	<u>Substrate</u>	<u>Nucleophile</u>	<u>Product</u>	<u>Yield</u>
	LysOET	Methionine amide	LysMetNH ₂	81%
	LysOET	Tryptophane amide	LysTrpNH ₂	32%
	LysOET	Alanine amide	LysAlaNH ₂	5%
15	HisOET	Methionine amide	HisMetNH ₂	62%

a) 10 μ M

20

25

30

35

- 24 -
Example 4

Alpha-Chymotrypsin a) catalyzed synthesis of L,L-dipeptide amides using L-Tyrosine ethyl ester (50 mM) as substrate and
5 L-amino acid amides as nucleophiles in water

	<u>Nucleophile</u>	(conc.)	pH	<u>Product</u>	<u>Yield</u>
10	Leucine amide	(0.2 M)	9.0	TyrLeuNH ₂	68%
	Arginine amide	(0.4 M)	8.5	TyrArgNH ₂	90%
	Serine amide	(0.4 M)	8.5	TyrSerNH ₂	75%

15 a) 5 μ M

20

25

30

35

- 25 -
Example 5

Alpha-Chymotrypsin a) catalyzed synthesis of L,D-dipeptide
5 amides using L-Tyrosine ethyl ester (5 or 50 mM) as substrate
and D-amino acid amides as nucleophiles in water

	Nucleophile	(conc.)	pH	Product	Yield
10	D-leucine amide	(0.2 M)	9.0	TyrlleuNH ₂	17% ^{b)}
	D-isoleucine amide	(0.3 M)	9.0	TyrileNH ₂	23% ^{b)}
	D-serine amide	(0.4 M)	8.5	TyrserNH ₂	35%

15

- a) 5 μ M
b) 5 mM substrate

20

25

30

35

- 26 -
Example 6

Alpha-Chymotrypsin catalyzed synthesis of D,L-dipeptide amide using D-tyrosine ethyl ester (50 mM) as substrate and L-Leucine amide as nucleophiles in water at pH 9.0

	<u>Nucleophile</u>	(conc.)	Product	<u>Yield^c)</u>
10	L-Leucine amide	(0.2 M)	D,L-tyrLeuNH ₂	40% ^a)
	L-Leucine amide	(0.3 M)	D,L-tyrLeuNH ₂	68% ^b)

- 15 a) 50 μ M enzyme
b) 100 μ M enzyme
c) Prolonged reaction time - days

20

25

30

35

- 27 -
Example 7

Alpha-Chymotrypsin a) catalyzed synthesis of L,L- and L,D-dipeptide amides and esters using different L-amino acid esters (50 mM) as substrates and L- or D-amino acid esters (0.8 M) or amides as nucleophiles at pH 8.5

10	<u>Substrate</u>	<u>Nucleophile</u>	<u>Solvent</u>	<u>Product</u>	<u>Yield^d)</u>
	L-PheOEt	L-ArgNH ₂ ^{b)}	Water	PheArgNH ₂	82%
	L-TyrOEt	L-SerOEt	Water	TyrSerOEt	48% ^{c)}
	L-TyrOBzl	L-SerOEt	30% DMF	TyrSerOEt	40% ^{c)}
15	L-TyrOBzl	L-SerOMe	30% DMF	TyrSerOMe	39% ^{c)}
	L-TyrOBzl	D-serOMe	30% DMF	TyrserOMe	21% ^{c)}

a) 5 μ M

20 b) 0.4 M nucleophile

c) at 90% conversion

d) hydrolysis/diketopiperazine formed due to chemical instability of product was observed under these conditions in amounts of 15-35% and is not included in the yields reported.

- 28 -
Example 8

Subtilisin A a) catalyzed synthesis of sidechain protected
5 L-Aspartyl-D-alanyl amide using L-Aspartyl diesters (0.1 M)
as substrates and D-alanine amide as nucleophile at pH 8.5

	Nucleophile				
10	Substrate	(conc.)	Solvent	Product	Yield
	L-Asp(OEt) ₂	(1.0 M)	Water	Asp(OEt)alaNH ₂	9%
	L-Asp(OEt) ₂	(2.0 M)	Water	Asp(OEt)alaNH ₂	24%
15	L-Asp(OBzl) ₂ ^{b)}	(0.5 M)	30% DMSO	Asp(OBzl)alaNH ₂	8%
	L-Asp(OBzl) ₂ ^{b)}	(1.0 M)	30% DMSO	Asp(OBzl)alaNH ₂	20%

a) 5 μ Mb) 50 mM substrate, 20 μ M enzyme

20

25

30

35

- 29 -
Example 9

Elastase a) catalyzed synthesis of L,L-amides using amino acid benzyl ester (50 mM) as substrate and amino acid amide (0.5 M) as nucleophile in water at pH 8.5

	<u>Substrate</u>	<u>Nucleophile</u>	<u>Product</u>	<u>Yield</u>
10	L-ValOBzl	L-Arginine amide	ValArgNH ₂	59%

a) 40 μ M
15

20

25

30

35

- 30 -
Example 10

Synthesis of L,L-dipeptide amides catalyzed by papaya thiol-
5 endoproteases^{a)} using amino acid esters (50 mM) as
substrates and L-amino acid amides (0.8 M) as nucleophiles
in water at pH 8.5

10	Enzyme	Substrate	Nucleophile	Product	Yield
	Papain	LysOEt	AlaNH ₂	LysAlaNH ₂	60%
	Papain	LysOMe	AlaNH ₂	LysAlaNH ₂	55%
	Chymopapain	LysOEt	AlaNH ₂	LysAlaNH ₂	23%
15	Chymopapain	LysOMe	AlaNH ₂	LysAlaNH ₂	34%

^{a)} 100 μ M, 2 mM EDTA, 10 mM Cysteine

20

25

30

35

- 31 -
Example 11

5 Clostripain a) catalyzed synthesis of L,L-dipeptide amides
and esters with L-Arginine ethyl ester as substrate (50 mM)
and L-amino acid amides as nucleophiles at pH 8.5

	<u>Nucleophile</u>	(conc.)	Solvent	Product	Yield
10	L-Methionine amide	(0.5 M)	Water	ArgMetNH ₂	38%
	L-Phenylalanine amide	(0.2 M)	30% EtOH	ArgPheNH ₂	6%
	L-Phenylalanine amide	(0.6 M)	30% DMF	ArgPheNH ₂	65%

15 a) 5 μ M enzyme, 50 mM CaCl₂, 10 mM DTT, pH adjusted with TEA

20

25

30

35

- 32 -
Example 12

Porcine Pancrease Lipase a) catalyzed synthesis of L,L-di-peptide amides using L-amino acid ethyl esters (50 mM) as substrates and L-amino acid amides as nucleophiles in 30% EtOH at pH 8.5

	<u>Substrate</u>	<u>Nucleophile (conc.)</u>	<u>Product</u>	<u>Yield</u>
	L-TrpOEt	L-MetNH ₂ (1.5 M)	TrpMetNH ₂	71%
	L-TrpOEt	L-MetNH ₂ (1.0 M)	TrpMetNH ₂	54%
	L-TyrOEt	L-SerNH ₂ (1.5 M)	TyrSerNH ₂	69%
15	L-MetOEt	L-MetNH ₂ ^{b)} (1.0 M)	MetMetNH ₂	31% ^{c)}

a) 500 μ M

b) Reaction in pure water

20 c) At incomplete conversion

25

30

35

- 33 -

Example 13

5 Candida Cylindracea Lipase a) catalyzed synthesis of L,L-di-peptide amides using L-amino acid ethyl esters (50 mM) as substrates and L-amino acid amides as nucleophiles in 30% EtOH at pH 8.5

10	<u>Substrate</u>	<u>Nucleophile (conc.)</u>	<u>Product</u>	<u>Yield</u>
	L-TrpOEt	L-MetNH ₂ (1.5 M)	TrpMetNH ₂	75% ^{b)}
	L-TyrOEt	L-SerNH ₂ (1.5 M)	TyrSerNH ₂	50% ^{b)}

15

a) 1000 μ M, prolonged reaction time

b) versus hydrolysis at less than 50% conversion

20

25

30

35

- 34 -
Example 14

Preparative synthesis of L,L-TryptophanylMethionine amide,
5 TrpMetNH₂

Procedure

- 10 L-Tryptophane ethyl ester hydrochloride (4.0 g, 15 mmol) and L-Methionine amide hydrochloride (55.7 g, 300 mmol) were dissolved in 195 ml H₂O and 90 ml ethanol, and pH was adjusted to 8.5 with sodium hydroxide. The reaction was initiated by addition of 0.8 g of crude Porcine Pancreatic Lipase and was kept at pH 8.5 for the duration of the reaction. The remainder of the substrate (4.0 g, 15 mmol) was added after 5 hours and the reaction continued overnight. It was then stopped by adjusting pH to 3 with HCl-solution.
- 15 20 The mixture was then diluted, ethanol was removed by evaporation under reduced pressure, and the mixture was filtered. The filtrate was purified by RP-preparative HPLC (Waters Prep LC/System 500A) using two columns (5.7 x 30 cm), packed with 60 um C-18 particles and 5 mM HCl/ethanol mixtures as eluent.
- 25

Collected fractions containing pure product were concentrated under reduced pressure and finally freeze dried.

- 30 This procedure gave 4.78 g of L,L-Tryptophanylmethionine amide hydrochloride (12.9 mmol, 43%) as an amorphous powder.

Identification

- 35 The product was identified as the hydrochloride containing 10.3% (w/w) of chloride.

- 35 -

Amino acid analysis showed the absence of free amino acids and gave the following results after acid hydrolysis:

Met (1.00)
5 Trp (1.00)

Specific optical rotation in 50% MeOH, c=0.2 using the sodium D-line was found to be +40.0° at 20°C.

10 Purity

HPLC-purity: 92.4% (Novapak 4 µm C-18, 0.1 M ammonium phosphate, pH 3.0/acetonitrile, 220 nm)

15 Water content by Karl Fisher: 5.3% (w/w)

Quantization of the alpha-amino group by reaction with Trinitrobenzene sulphonic acid and UV-detection: 75.8% (w/w).

20 Peptide content by UV-quantization: 88.3% (w/w) (281 nm, Trp-absorbance in MeOH: 0.1 N KOH (1:1))

25 .

30

35

- 36 -
Example 15

Preparative synthesis of L,D-Tyrosylserine amide, TyrserNH₂

5

Procedure

- 10 L-Tyrosine ethyl ester hydrochloride (2.5 g, 10 mmol) and D-serine amide hydrochloride (17.5 g, 100 mmol) were dissolved in 200 ml of water, and pH was adjusted to 8.5 with sodium hydroxide. The reaction was initiated by addition of 50 mg of alpha-chymotrypsin and was kept at pH 8.5 for the duration of the reaction. After 30 minutes precipitation of free tyrosine began. The remainder of the substrate (5.0 g, 20 mmol) was added in two portions of 2.5 g during 1 hour. The reaction was stirred for two hours and was then stopped by adjusting pH to 3 with HCl-solution.
- 15 20 The formed tyrosine was filtered off, and the filtrate was purified by RP-preparative HPLC (Waters Prep LC/System 500A) using two columns (5.7 x 30 cm) packed with 20 μM C-18 particles and 50 μM acetic acid as an eluent.
- 25 30 Collected fractions containing pure product were concentrated under reduced pressure and finally freeze dried with addition of aqueous HCl.
- This procedure gave 2.8 g of L,D-Tyrosylserine amide hydrochloride (9.2 mmol, 31%) as an amorphous powder.

Identification

- The product was identified as the hydrochloride containing 35 16.0% (w/w) of chloride.

- 37 -

Amino acid analysis showed the absence of free amino acids, but following acid hydrolysis gave the following results:

5 Ser (1.10)
 Tyr (0.90)

Specific optical rotation in 50% MeOH, c=0.3 using the sodium D-line was found to be +58.0° at 20°C.

10 Purity

HPLC-purity: 97.4% (Novapak 4 µm C-18, 0.1 M ammonium phosphate, pH 3.0/acetonitrile, 220 nm)

15 Water content by Karl Fisher: 1.8% (w/w).

Quantization of the alpha-amino group by reaction with Trinitrobenzene sulphonic acid and UV-detection: 81% (w/w).

20

25

30

35

- 38 -
Example 16

Preparative synthesis of D,L-tyrosylLeucin amide, tyrLeuNH₂

5

Procedure

D-tyrosine ethyl ester hydrochloride (3.5 g, 14 mmol) and
10 L-Leucin amide hydrochloride (14 g, 84 mmol) were dissolved
in 246 mL of 0.1 M KCl and pH was adjusted to 9.0 with sodium
hydroxide. The reaction was initiated by addition of 0.7
g of alpha-chymotrypsin and stirred for two days at room
temperature. pH was kept at 9.0 for the duration of the re-
action. The reaction was stopped by adjusting pH to 3 using
15 HCl-solution.

The formed tyrosine was filtered off, and the filtrate was
purified by RP-preparative HPLC (Waters Prep LC/System 500A)
20 using two columns (5.7 x 30 cm) packed with 20 μM C-18 par-
ticles and 5 mM HCl as an eluent.

Collected fractions containing pure product were concentra-
25 ted by evaporation under reduced pressure and finally freeze
dried.

This procedure gave 2.50 g of D,L-tyrosylLeucine amide hy-
drochloride (7.6 mmol, 54%) as an amorphous powder.

30 Identification

The product was identified as the hydrochloride containing
9.8% (w/w) of chloride.

35

- 39 -

Amino acid analysis showed the absence of free amino acids, but following acid hydrolysis gave the following results:

Tyr (0.98)
5 Leu (1.03)

Specific optical rotation in water, c=0.1 using the sodium D-line was found to be -129.4° at 20°C.

10 Purity

HPLC-purity: 92.9% (Novapak 4 um C-18, 0.1 M ammonium phosphate, pH 3.0/acetonitrile, 220 nm)

15 Water content by Karl Fisher: 6.8% (w/w).

Quantization of the alpha-amino group by reaction with Tri-nitrobenzen sulfonic acid and UV-detection: 74.9%

20 UV-quantization: 74.9% (Tyrosine phenolate absorbance at 293 nm, in 0.1 M KOH)

25

30

35

- 40 -

Example 17

5 Preparative synthesis of L,L-ArginylMethionine amide, Arg-MetNH₂,

Procedure

10 L-Arginine ethyl ester dihydrochloride (4.1 g, 15 mmol) and L-Methionine amide hydrochloride (55.4 g, 300 mmol) were dissolved in 300 ml of water, and pH was adjusted to 8.5 with sodium hydroxide. The reaction was initiated by addition of 50 mg of trypsin. pH was kept at 8.5 for the duration of the reaction. The remainder of the substrate (8.2 g, 15 30 mmol) was added during one hour. The reaction was then stopped by adjusting pH to 3 using HCl-solution.

20 The reaction mixture was then diluted and purified by successive cation exchange on a DOWEX A650 Wx4 and a CM-Sephadex rose 6B column using ammonium acetate and NaCl/HCl salt gradients, respectively, and was finally desalted.

25 Collected fractions containing pure product were concentrated under reduced pressure and finally freeze dried.

This procedure gave 10.7 g of L,L-ArginylMethionine amide dihydrochloride (28.3 mmol, 63%) as a white amorphous powder.

30 Identification

Less than 0.2% (w/w) of acetate and 22.9% (w/w) of chloride were measured, so the product was present as a dihydrochloride.

- 41 -

Amino acid analysis showed the absence of free amino acids, but following acid hydrolysis gave the following results:

Arg (1.00)
5 Met (0.80)

Specific optical rotation in 50% MeOH, c=0.2 using the sodium D-line was found to be +19.5° at 20°C.

10 Purity

HPLC-purity: 95.1% (Novapak C-18, 0.1 M ammonium phosphate containing alkylsulfonate, pH 4.5/acetonitrile, 220 nm)

15 Water content by Karl Fisher: 9.1% (w/w).

Peptide content by amino acid analysis: 72% (w/w) based on Arginine.

20

25

30

35

- 42 -

Example 18

5 Synthesis of L,L-Methionyl-Methionine amide catalyzed by Eu-
 pergit C immobilized Porcine Pancreatic Lipase a) using
 L-Methionine ethyl ester as substrate and L-Methionine amide
 as nucleophile at pH 8.5 in water and water/organic homoge-
 neous mixtures.

10	Conc. of substrate	Nucleophile	%	Organic solvent	Yield b)
	50 mM	1.0 M	0	-	68%
15	100 mM	0.5 M	30	Isopropanol	26%

20 a) Porcine Pancreatic Lipase was immobilized on Eupergit C
 using the procedure recommended by the manufacturer to a
 final concentration corresponding to approx. 400 μ M on
 the gel by activity assay.

25 b) The reaction mixtures with volumes of 1-3 reaction bed
 volumes were recirculated over the column packed with en-
 zyme gel until full conversion of the substrate as deter-
 mined by HPLC (0.5-2 days) while pH was being kept con-
 stant by pH-stat control.

- 43 -

Example 19

5 Porcine Pancreatic Lipase a) and alpha-chymotrypsin a) cata-
 lyzed synthesis of L,L-Tryptophanyl-Alanine-tert-butylester
 in pure organic solvents with L-Tryptophane ethyl ester (50
 mM) as substrate and L-Alanine-tert-butylester (0.3 M) as
 nucleophile, both in saltfree form.

10

	<u>Enzyme a)</u>	<u>Solvent</u>	<u>Conversion c)</u>	<u>Yield c)</u>
	PPL	CH ₂ Cl ₂ /n-Hexane (1:3)	30%	13%
	CT	CH ₂ Cl ₂ /n-Hexane (1:3)	56%	17%
15	PPL	CH ₂ Cl ₂	7%	10%
	CT	CH ₂ Cl ₂	50%	3%
	PPL b)	CH ₂ Cl ₂ /Isooctane (1:1)	82% b)	26%

20 a) 500-2000 µM freezedried enzyme containing moisture was
 added directly to the mixture, which was stirred for 24
 hours.

25 b) In this case, 500 µM enzyme and 3 days of reaction time
 were applied.

c) Conversion of starting material and yield versus hydroly-
 sis was determined by HPLC of samples quenched with DMF,
 evaporated and redissolved in DMF/acid water. Controls
 30 showed neither conversion nor yield.

- 44 -

Example 20

Alpha-chymotrypsin a) catalyzed synthesis of sidechain protected L,L-dipeptide amides with L-Tyrosine or L-Phenylalanine ethyl esters (50 mM) as substrates and L-S-Acetamidomethylcysteine amide (0.6 M) as nucleophiles in water at pH 8.5.

10

	<u>Substrate</u>	<u>Product</u>	<u>Yield</u>
	L-Tyrosine ethyl ester	TyrCys(-SAc) _m NH ₂	62%
	L-Phenylalanine ethyl ester	PheCys(-SAc) _m NH ₂	78%

15

a) 5 μ M

20

25

30

35

- 45 -

Example 21

Alpha-chymotrypsin a) catalyzed synthesis of L,L-Dipeptide alcohols using L-Tyrosine and L-Phenylalanine ethyl esters (50 mM) as substrates and L-Amino acid alcohols (0.5 M) as nucleophiles in water at pH 8.5.

10	<u>Substrate</u>	<u>Nucleophile</u>	<u>Product</u>	<u>Yield</u>
	L-TyroEt	L-MetCH ₂ OH	TyrMetCH ₂ OH	42%
15	L-TyroEt	L-LeuCH ₂ OH	TyrLeuCH ₂ OH	46%
	L-PheEt	L-MetCH ₂ OH	PheMetCH ₂ OH	60%

a) 10 μ M

20

25

30

35

- 46 -

Example 22

Synthesis of L,L-dipeptides catalyzed by thiolendoproteases

- 5 a) using amino acid ethyl esters (50 mM) as substrate and free L-Amino acids as nucleophiles in water at pH 8.5.

<u>Enzyme</u>	<u>Substrate</u>	<u>Nucleophile</u>	<u>(conc.)</u>	<u>Product</u>	<u>Yield b)c)</u>
---------------	------------------	--------------------	----------------	----------------	-------------------

10	Ficin	ArgOEt	ArgOH	(1.0 M)	ArgArgOH 6%
	Papain	ArgOEt	ArgOH	(1.0 M)	ArgArgOH 7%
	Ficin	LysOEt	AlaOH	(1.5 M)	LysAlaOH 5%
	Papain	LysOEt	AlaOH	(1.5 M)	LysAlaOH 6%

15

a) 100 μ M, 2 mM EDTA, 0.1 M KCl, 5 mM DTT or 10 mM cysteine.

b) Determined vs. hydrolysis via a standard at less than 50% conversion.

20

c) Controls without enzyme showed no detectable aminolysis under the conditions reported.

- 47 -

Example 23

Trypsin a) catalyzed synthesis of L,L-dipeptide amides with
5 Arginine-paranitroanilide (10 mM) as substrate and L-Amino
acid amides (0.3 M) as nucleophiles in 40% DMF at pH 8.5.

	<u>Nucleophile</u>	<u>Product</u>	<u>Yield b)</u>
10	Methionine amide	ArgMetNH ₂	45%
	Leucine amide	ArgLeuNH ₂	31%
	Tyrosine amide	ArgTyrNH ₂	14%

15

a) 5 μ M

b) Determined vs. hydrolysis via a standard at less than 80% conversion.

20

25

30

35

- 48 -

Example 24

5 Papain a,b) catalyzed synthesis of L,L-Lysyl-Alanine amide
using L-Lysine ethyl ester (50 mM) as substrate and L-Alanine
amide (0.8 M) as nucleophile in water at various pH-values.

10	pH	Yield c)
	6.5	21%
	4.5	47%

- 15 a) 50 μ M, 2 mM EDTA, 10 mM Cysteine.
b) At prolonged reaction time; less than 50% conversion.
20 c) Determined vs. hydrolysis using a standard and corrected
for incomplete conversion.

25

30

35

- 49 -

Example 25

Alpha-chymotrypsin a) and clostripain b) catalyzed synthesis
5 of L,L-dipeptide esters using L-Amino acid ethyl esters (50 mM) as substrates and L-Amino acid ethyl or tert-butyl-esters as nucleophiles in water at pH 7.5 and 8.5.

10	Enzyme	Substrate	Nucleophile	(conc.)	Product	Yield
	CT	TrpOEt	AlaOtBu	(0.8 M)	TrpAlaOtBu	12%
	CT	TrpOEt	ValOEt	(0.8 M)	TrpValOEt	18%
15	CL	ArgOEt	MetOEt	(1.0 M)	ArgMetOEt	33% c)

a) 5 μ M, 0.1 M KCl, pH 7.5.

b) 10 μ M, 50 mM CaCl₂, 10 mM DTT, pH 8.5 adjusted with TEA.

20 c) Determined at less than 50% conversion.

25

30

35

- 50 -

Example 26

5 Porcine Pancreatic Lipase a) and Lipolase (Novo)(LIP) a) and Rhizopus Arrhizus Lipase (RA) b) catalyzed synthesis of L,L-Methionyl-Methionine amide using different L-Methionine esters as substrates and L-Methionine amide as nucleophile in various aqueous/organic solvent homogeneous mixtures at pH 8.5 and 1.0 M nucleophile, unless otherwise indicated.

10

		Ester substrate	(conc.)	%	Organic solvent	Yield e)
15	PPL c)	Ethyl	(50 mM)	0	-	55%
	PPL d)	Ethyl	(50 mM)	0	-	36%
	PPL	Ethyl	(150 mM)	0	-	42%
	PPL	Ethyl	(200 mM)	15	Dimethoxy Ethane	20%
	PPL	Ethyl	(150 mM)	30	Isopropanol	36%
20	PPL	Ethyl	(50 mM)	90	Ethylene Glycol	42%
	PPL	n-Propyl	(50 mM)	0	-	55%
	PPL	n-Hexyl	(50 mM)	0	-	39%
	LIP	Ethyl	(50 mM)	0	-	47%
	LIP	Ethyl	(50 mM)	15	Dimethoxy Ethane	35%
25	LIP	n-Hexyl	(50 mM)	0	-	32%
	RA	Ethyl	(50 mM)	30	Ethanol	23%

a) 1000 μ M - 2000 μ M

30 b) 50 μ M

c) pH 9.0

d) At 0.25 M nucleophile

e) Various minor amounts of deamidation of product was noted under these conditions and is not included in the yields reported.

35

- 51 -

Example 27

5 Trichoderma Viridae Cellulase catalyzed synthesis of
L,L-TyrGlyNH₂ using L-Tyrosine ethyl ester as a substrate
and Glycine amide as nucleophile in water.

	<u>Substrate (conc.)</u>	<u>Nucleophile (conc.)</u>	<u>Product</u>	<u>Yield c)</u>
10	TyrOEt a) (20 mM)	GlyNH ₂	(0.6 M)	TyrGlyNH ₂ 23%
	TyrOEt b) (10 mM)	GlyNH ₂	(0.8 M)	TyrGlyNH ₂ 34%

- 15 a) 1000 μM crude enzyme, pH 8.5
b) 500 μM crude enzyme, pH 8.0

20 c) Determined vs. hydrolysis at less than 30% conversion and
corrected for hydrolysis and aminolysis found in con-
trols at similar conditions.

25

30

35

P a t e n t C l a i m s :


1. A process for producing dipeptides or structurally
5 related compounds having the general formula



wherein A represents an optionally side-chain protected L-
10 or D- α -amino acid residue or ω -amino acid residue and B
represents an optionally side-chain protected L- or D- α -
aminocarboxylic acid residue which may be the same as or
different from A, an L- or D-aminophosphonic acid residue
15 or L- or D-aminosulfonic acid residue or the corresponding
15 ω -amino acids or salts and hydrates thereof, and Y is OH,
H, alkyl, aryl, aralkyl or a C-terminal blocking group, or
BY represents an amino alcohol residue



20 wherein B^1 is a decarboxy derivative of the amino-
carboxylic acids as defined with relation to B, and Y^1 is
H, alkyl, aryl or aralkyl, characterized by
reacting a substrate component, which is an amino acid
25 derivative having the formula



30 wherein A is as defined above, R^1 represents alkyl, aryl
or aralkyl optionally substituted with inert substituents
or an α -des-amino fragment of an amino acid, and R^2 and
 R^3 are the same or different and each represents hydrogen,
35 alkyl, aryl or aralkyl optionally substituted with inert
substituents,


with a nucleophile component selected from

(a) amino acids having the formula

5 H-B-OH

wherein B is an aminocarboxylic acid residue as defined above,

10 (b) amino acid amides having the formula




15

wherein B is an aminocarboxylic acid residue as defined above, and R² and R³ have the above meaning, except that when R² represents hydrogen, R³ may also represent hydroxy or amino,

20

(c) amino acid esters having the formula




25 wherein B is an aminocarboxylic acid residue as defined above, and R' represents alkyl, aryl or aralkyl,

(d) optionally acid group protected straight chain or branched aminophosphonic acids or aminosulfonic acids having the formula



wherein R⁵, R⁶ and R⁷ independently represent hydrogen,
35 alkyl, aryl or aralkyl, x is 1-6 and z is 2-12,

(e) amino acid aldehydes or ketones or derivatives thereof having the formula



5

wherein B^1 is as defined above, Y^2 is O or a functional derivative thereof, preferably a ketal, and R^8 is H, alkyl, aryl or aralkyl, and

10 (f) amino alcohols having the formula



wherein B^1 and Y^1 have the above meaning

15

in the presence of an amidase or esterase enzyme different from serine or thiol carboxypeptidases in solution or dispersion, and then, if desired, cleaving a present side-chain protecting group or protective group Y and/or, if 20 desired, converting the resulting dipeptide derivative to a salt or hydrate.

2. A process according to claim 1, characterized -
25 i z e d by using an enzyme with esterase or amidase activity selected from serine or thiolendoproteases, lipases, esterases and glycosidases.

3. A process according to claim 1 or 2, characterized in that the enzyme used has been chemically 30 modified or is a biosynthetic mutant of a natural form.

4. A process according to any of the preceding claims, characterized by using an immobilized enzyme.

35 5. A process according to any of the preceding claims, characterized by using an aqueous reaction

solution or dispersion containing 0-90%, preferably 0-60%, of a polar water miscible organic solvent and having a pH value of 3-11, preferably 5-10.5, more preferably 6-10, in particular 7-9.5.

5

6. A process according to claim 5, characterized in that the organic solvent is selected from alkanols, dimethyl sulfoxide, dimethyl formamide, dimethoxy ethane and ethylene glycol.

10

7. A process according to any of claims 1 to 4, characterized by using an organic reaction solution or dispersion containing 0-10% of water.

15

8. A process according to claim 7, characterized by using an unpolar organic solvent, preferably selected from dialkyl ethers, ethyl acetate, ethyl propionate, octanes, heptanes, hexanes, petroleum ether and methylene chloride.

20

9. A process according to claim 7, characterized by using a liquid substrate or nucleophile component which may also serve as the organic solvent.

25

10. A process according to any of the preceding claims, characterized by using as substrate component a D- or L-amino acid ester selected from benzyl esters or straight or branched C₁-C₈ alkyl esters optionally substituted with inert substituents.

30

11. A process according to any of the preceding claims, characterized by using as nucleophile component an amino acid amide having the formulae

35

H-B-NHR'

wherein R' is hydrogen or C₁-C₃ alkyl and B is an L- or D-amino carboxylic acid residue.

12. A process according to any of claims 1 to 10,
5 characterized by using as nucleophile component an ester having the formula



- 10 wherein B is a L- or D-aminocarboxylic acid residue and R' is C₁-C₃ alkyl.

13. A process according to any of the preceding claims, characterized in that the resulting dipeptide 15 includes one or more C-terminal protective groups Y, and that the group or groups are cleaved enzymatically, either by means of the same enzyme as was used in the preceding reaction or by means of an enzyme having a different ester or amide specificity.

- 20
14. A process according to any of the preceding claims, characterized in that the resulting dipeptide includes one or more side-chain protective groups and that the group or groups are cleaved enzymatically, preferably 25 by means of an esterase or lipase or proteolytical enzyme.

INTERNATIONAL SEARCH REPORT

International Application No PCT/DK89/00193

I. CLASSIFICATION OF SUBJECT MATTER (If several classification symbols apply, indicate all) *

According to International Patent Classification (IPC) or to both National Classification and IPC 4

C 12 P 21/02, C 07 K 1/00

II. FIELDS SEARCHED

Minimum Documentation Searched *

Classification System	Classification Symbols
IPC 4	C 07 K 1/00-/14; C 12 P 21/00,/02
US Cl	435:68-70; 195:4,29,30

Documentation Searched other than Minimum Documentation
to the Extent that such Documents are Included in the Fields Searched *

SE, NO, DK, FI classes as above.

III. DOCUMENTS CONSIDERED TO BE RELEVANT*

Category *	Citation of Document, * with indication, where appropriate, of the relevant passages **	Relevant to Claim No. ***
Y	EP, A2, 0 269 390 (GENENCOR INC.) 1 June 1988 see page 2 lines 33-60	1-14
Y	EP, A2, 0 220 923 (W.R. GRACE & CO) 6 May 1987 see claim 1 & EP, 86308176 US, 4710583 US, 4810817 JP, 62142199	1-14
Y	EP, A1, 0 074 095 (TOYO SODA MANUFACTURING CO., LTD) 16 March 1983 & EP, 82108117 JP, 58043793 US, 4506011 CA, 1195272 JP, 58063394	1-14

.../...

* Special categories of cited documents: 10

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the International filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the International filing date but later than the priority date claimed

"T" later document published after the International filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"Z" document member of the same patent family

IV. CERTIFICATION

Date of the Actual Completion of the International Search

Date of Mailing of this International Search Report

1989-10-23

1989 -11- 14

International Searching Authority

Signature of Authorized Officer

Swedish Patent Office

Yvonne Siösteen

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)		
Category	Citation of Document, with indication, where appropriate, of the relevant passages	Relevant to Claim No.
Y	EP, A2, 0 154 472 (AJINOMOTO CO., INC.) 11 September 1985 & EP, 85301229 JP, 60186299 US, 4666838 JP, 61035796	1-14
Y	EP, A1, 0 017 485 (DE FORENEDE BRYGGERIER A/S) 15 October 1980 see page 5, lines 1-5, pages 6-7 and the claims & WO, 80/02157 US, 4339534 CA, 1160973 AT, E, 9595 CA, 1177429 AU, 545416 US, 4806473	1-14
P,X	EP, A1, 0 278 787 (CARLSBERG BIOTECHNOLOGY LTD. A/S) 17 August 1988 & WO, 88/06187	1-14